H.C. Wainwright maintained a positive outlook on Axsome Therapeutics (NASDAQ:AXSM), reiterating a Buy stock rating with a ...
HC Wainwright reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $42.00 ...
HC Wainwright restated their buy rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a research report released on Tuesday,Benzinga reports. They currently have a $18.00 price ...
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Disc Medicine (IRON – Research Report) today and set a price target of $118.00.
H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...
BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the“Company”), a leader in blockchain infrastructure and technology, has announced its ...
Fintel reports that on January 17, 2025, HC Wainwright & Co. downgraded their outlook for CECO Environmental (NasdaqGS:CECO) ...
Microbot Medical Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of 51.85%. The profit margin, also known as the revenue ratio or gross profit ratio, ...
H.C. Wainwright lowered the firm’s price target on Jasper Therapeutics (JSPR) to $40 from $60 and keeps a Buy rating on the shares after the company announced initial data from the BEACON study ...
H.C. Wainwright initiated coverage of MetaVia (MTVA) with a Buy rating and $12 price target The company’s DA-1726 is a novel oxyntomodulin analogue designed as a dual agonist targeting glucagon ...
https://www.tipranks.com/news/the-fly/paragon-28-sees-q4-revenue-71-5m-71-8m-consensus-69-62m H.C. Wainwright notes VYNE Therapeutics (VYNE) disclosed positive ...
RAPT Therapeutics (NASDAQ:RAPT) shares rose on Thursday after H.C. Wainwright upgraded the immunology-focused biotech to Buy from Neutral based on the company's recent licensing deal with China's ...